Literature DB >> 16919856

Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlands.

Robin van Houdt1, Gerard J B Sonder, Nicole H T M Dukers, Lian P M J Bovee, Anneke van den Hoek, Roel A Coutinho, Sylvia M Bruisten.   

Abstract

To evaluate hepatitis B virus (HBV) risk group vaccination in Amsterdam, which started in 1998, we examined 342 reported acute HBV-cases and sequenced 85 DNA isolates. The reported number of cases declined from 214 in 1992-1997 to 128 in 1998-2003, due to a decline in injecting drug users (IDU) and their heterosexual partners. Phylogenetic analyses showed that after 1998, the IDU cluster nearly disappeared, probably due to a decline in injecting. Acute HBV remained stable among men having sex with men; given their increased sexual risk behavior, vaccination has probably prevented an increase in their acute infections. Currently, 48-72% of the people who should be included in the program are still susceptible to HBV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919856     DOI: 10.1016/j.vaccine.2006.06.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial.

Authors:  Lu-Yu Hwang; Carolyn Z Grimes; Thanh Quoc Tran; April Clark; Rui Xia; Dejian Lai; Catherine Troisi; Mark Williams
Journal:  J Infect Dis       Date:  2010-10-11       Impact factor: 5.226

2.  Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men.

Authors:  Thijis van de Laar; Oliver Pybus; Sylvia Bruisten; David Brown; Mark Nelson; Sanjay Bhagani; Martin Vogel; Alex Baumgarten; Marie-Laure Chaix; Martin Fisher; Hannelore Gotz; Gail V Matthews; Stefan Neifer; Peter White; William Rawlinson; Stanislav Pol; Jurgen Rockstroh; Roel Coutinho; Greg J Dore; Geoffrey M Dusheiko; M Danta
Journal:  Gastroenterology       Date:  2009-05       Impact factor: 22.682

3.  Genetic variation of hepatitis B surface antigen among acute and chronic hepatitis B virus infections in The Netherlands.

Authors:  Jeroen Cremer; Sanne H I Hofstraat; Francoise van Heiningen; Irene K Veldhuijzen; Birgit H B van Benthem; Kimberley S M Benschop
Journal:  J Med Virol       Date:  2018-06-07       Impact factor: 2.327

Review 4.  Bloodborne viral hepatitis infections among drug users: the role of vaccination.

Authors:  Fabio Lugoboni; Gianluca Quaglio; Paolo Civitelli; Paolo Mezzelani
Journal:  Int J Environ Res Public Health       Date:  2009-01-22       Impact factor: 3.390

5.  How hepatitis D virus can hinder the control of hepatitis B virus.

Authors:  Maria Xiridou; Barbara Borkent-Raven; Joost Hulshof; Jacco Wallinga
Journal:  PLoS One       Date:  2009-04-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.